(36 days)
The 3160 MRI Patient Monitoring System is intended to monitor vital signs for patients undergoing MRI procedures and to provide signals for synchronization for the MRI scanner. The 3160 MRI Patient Monitoring System is intended for use by health care professionals.
The 3160 MRI Patient Monitoring System is intended to monitor vital signs for patients undergoing MRI procedures and to provide signals for synchronization for the MRI scanner. It is designed to assist clinicians in monitoring patient vital signs in the MRI the dynamic and evolving Magnetic Resonance environment. A combination of wireless communication, radio frequency (RF) shielding, digital signal processing (DSP), and adaptable mounting technologies address the challenges associated with patient monitoring in the MRI area. Built on Invivo's strong heritage in MRI patient vital signs monitoring, the 3160 MRI Patient Monitoring System provides accurate, continuous, and reliable performance during all phase of MRI applications.
This document describes the 3160 MRI Patient Monitoring System, a device intended to monitor vital signs for patients during MRI procedures. The submission focuses on demonstrating substantial equivalence to previously cleared predicate devices rather than a standalone clinical study with expert ground truth or AI performance metrics.
Here's a breakdown of the requested information based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The device's acceptance criteria are presented as "Specification" and the reported performance as "Pass" within the tables below.
| Parameter | Specification | Reported Device Performance |
|---|---|---|
| End Tidal CO2 Monitoring (Capnometer) | ||
| Measurement Range | 0-76 mmHg | Pass |
| Accuracy | ±2mmHg + 5% of reading | Pass |
| Flow Rate | 50 mL/min | Pass |
| Respiration Rate | 0 to 100 BPM | Pass |
| Zero Drift Rate | 0.5 mmHg/hr; 1.5 mmHg/24hr | Pass |
| Alarm Limits | Lower: Off, 5 to 60 mmHg; Upper: Off, 5 to 80 mmHg | Pass |
| Inspired CO2 | 25 mmHg | Pass |
| Invasive Pressure Monitoring | ||
| Channels | 1 or 2 simultaneous channels | Pass |
| Bandwidth (-3dB) | 0 to 12 Hz | Pass |
| Range | -10 to +248 mmHg | Pass |
| Sensitivity | 5 uV/V/mmHg | Pass |
| Gain Accuracy | ± 0.5 % | Pass |
| Auto Zero Feature | Zeroes with +/- 300 mmHg offset to 0+/- 5 mmHg within 1 second | Pass |
| Waveform Display Scales | 0 to 45, 0 to 75, 0 to 150, 0 to 200, 0 to 250 mmHg | Pass |
| High Pressure Alarm | 5 to 248 mmHg range; 1 mmHg resolution | Pass |
| Low Pressure Alarm | 5 to 248 mmHg range; 1 mmHg resolution | Pass |
| Temperature Monitoring | ||
| Temperature Range | 25 to 44°C (77° to 111.2°F) | Pass |
| Accuracy | ± 0.5°C (± 0.5°F) | Pass |
| Resolution | ± 0.1°C (± 0.18°F) | Pass |
| Respiration Monitoring | ||
| Range | 4 to 150 BPM | Pass |
| Resolution | 1 BPM | Pass |
| Accuracy | 2% to 60 BPM, 3.4% at 87 BPM, 5.6% at 142 BPM | Pass |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify a distinct "test set" in the context of human-reviewed data or a training/validation split common in AI/machine learning studies. The performance data is based on "Validation and Verification Testing" using simulators and test equipment.
- Sample Size: Not applicable in the context of distinct patient data sets. The testing involved "simulators and test equipment under actual use conditions" and two specific MRI scans (TRUE-FISP and PLANAR-ECHO) in a 3.0T MRI system.
- Data Provenance: Not human-derived patient data. The testing was conducted using simulators and test equipment within a specific (3.0T) MRI environment. It is a non-clinical, controlled laboratory/engineering testing environment, not retrospective or prospective patient data from a specific country.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Experts
Not applicable. The performance testing described is engineering verification and validation against specified technical parameters, not a clinical study requiring expert interpretation of medical images or patient outcomes. The "ground truth" here is the known output of the simulators and test equipment against which the device's measurements are compared.
4. Adjudication Method for the Test Set
Not applicable. There was no clinical ground truth established by experts requiring adjudication. The device's measurements were compared against known values from test equipment.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This submission focuses on the technical performance of a vital sign monitoring device and its substantial equivalence to predicate devices, not on the improvement of human reader performance with AI assistance. The device itself is a physiological monitoring system, not an AI diagnostic tool for interpreting medical images.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, the performance data presented is effectively a standalone evaluation of the device's functional modules (e.g., capnometer, invasive pressure, temperature, respiration) against established technical specifications using test equipment. There is no "human-in-the-loop" component in this performance testing as described. The performance data assesses the accuracy of the device's sensors and algorithms in measuring vital signs under simulated conditions.
7. The Type of Ground Truth Used
The ground truth used for the performance testing was derived from simulators and test equipment under controlled, actual-use (MRI environment) conditions. This is a technical or engineering ground truth, where the expected values are known and precisely controlled by the testing apparatus.
8. The Sample Size for the Training Set
Not applicable. This submission describes the performance of a physiological monitoring device, not an AI or machine learning algorithm that requires a training set of data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there was no training set for an AI/machine learning algorithm.
{0}------------------------------------------------
・
510(K) NOTIFICATION 3160 MRI PATIENT MONITORING SYSTEM
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
SUBMITTER INFORMATION
| A. | Company Name: | Invivo Corporation |
|---|---|---|
| B. | Company Address: | 12601 Research ParkwayOrlando, FL 32826 |
| C. | Company Phone:Company Fax: | (407) 275-3220(407) 206-9658 |
| D. | Contact Person: | John RacetteQuality Assurance and Regulatory Affairs ManagerInvivo Corporation |
| E. | Date Summary Prepared: | December 2, 2005 |
DEVICE IDENTIFICATION
| A. | Generic Device Name: | MRI compatible multiparameter patient monitor |
|---|---|---|
| B. | Trade/Proprietary Name: | 3160 MRI Patient Monitor |
| C. | Classification: | Class II |
D. Product Codes:
| Classification Names | Code | CFR Ref | |
|---|---|---|---|
| 1. | Monitor, Cardiac | DRT | 870.2300 |
| 2. | Monitor, Blood Pressure, Non-Invasive | DXN | 870.1130 |
| 3. | Oximeter | DQA | 870.2700 |
| 4. | Analyzer, Gas, Carbon Dioxide, Gaseous Phase | CCK | 868.1400 |
| 5. | Analyzer, Gas, Enflurane, Gaseous Phase | CBQ | 868.1500 |
| 6. | Analyzer, Gas, Halothane, Gaseous Phase | CBS | 868.1620 |
| 7. | Analyzer, Gas, Nitrous Oxide, Gaseous Phase | CBR | 868.1700 |
| 8. | Analyzer, Gas, Oxygen, Gaseous Phase | CCL | 868.1720 |
| 9. | Blood Pressure Computer (Invasive Blood Pressure) | DSK | 870.1110 |
| 10. | Thermometer, Electronic, Clinical | FLL | 880.2910 |
| 11. | Monitor, Breathing Frequency | BZQ | 868.2375 |
| 12. | Monitor, physiological, patient | MWI | 870.2300 |
DEVICE DESCRIPTION
The 3160 MRI Patient Monitoring System is intended to monitor vital signs for patients undergoing MRI procedures and to provide signals for synchronization for the MRI scanner. It is designed to assist clinicians in monitoring patient vital signs in the MKI
the dynamic and evolving Massatio Recess in monitoring patient vital signs in the mi the dynamic and evolving Magnetic Resonance environmoning patis
Confidential
Page 5-1
{1}------------------------------------------------
A combination of wireless communication, radio frequency (RF) shielding, digital signal processing (DSP), and adaptable mounting technologies address the challenges associated with patient monitoring in the MRI area. Built on Invivo's strong heritage in MRI patient vital signs monitoring, the 3160 MRI Patient Monitoring System provides accurate, continuous, and reliable performance during all phase of MRI applications.
SUBSTANTIAL EQUIVALENCE
The 3160 MRI Patient Monitoring System is of comparable type and is substantially equivalent to the following predicate devices:
| Predicate Device | Manufacturer | 510(k) No. | Date Cleared |
|---|---|---|---|
| 3160 MRI PatientMonitoring System | Invivo Research, Inc. | K050399 | 08/26/05 |
| Magnitude 3150/3155 MRIPatient Monitoring System | Invivo Research, Inc. | K040915 | 09/22/04 |
| Integrated PatientMonitoring System | Invivo Research, Inc. | K041918 | 10/15/04 |
| Polaris 2004 Capnograph | Oridion Medical Ltd | K040011 | 05/13/04 |
INTENDED USE
The 3160 MRI Patient Monitoring System is intended to monitor vital signs for patients undergoing MRI procedures and to provide signals for synchronization for the MRI scanner. The 3160 MRI Patient Monitoring System is intended for use by health care professionals.
COMPARISON TO PREDICATE DEVICE:
The primary differences between this device and the predicate 3160 MRI Patient Monitoring System are as follows:
- The end-tidal CO2 monitoring option is the same as that incorporated into the . predicate 3160 MRI Patient Monitoring System (K050399), except that
- the sensor is smaller, which in turns allows for a smaller flow rate, .
- the detector material has been changed from a thermopile to zinc selenium, .
- one detector is used to read both the patient gas and the baseline reference. .
This same technology is used in the Oridion Medical Ltd Polaris 2004 Capnograph, which was cleared to market under 510(k) K040011.
- The invasive blood pressure monitoring option is exactly the same as that used in the . Magnitude™ MRI Monitoring System (K040915).
- The temperature monitoring option is exactly the same as that used in the . Magnitude™ MRI Monitoring System (K040915).
- The respiration monitoring option is exactly the same as that used in the Integrated . Patient Monitoring System, which was cleared to market under 510(k) K041918.
Confidential
{2}------------------------------------------------
TECHNOLOGICAL CHARACTERISTICS
A comparison of the technological characteristics of the 3160 MRI Patient Monitoring System and the predicate devices has been performed. The results of this comparison demonstrate that the 3160 MRI Patient Monitoring System is equivalent to the marketed predicate devices in technological characteristics.
ENVIRONMENTAL AND NON-CLINICAL TESTING:
Applicable environmental and non-clinical testing was performed per UL60601 and EN IEC 60601-1-2 as well as other applicable particular standards and procedures. The 3160 MRI Patient Monitoring System passed all tests.
PERFORMANCE DATA
The performance data included in this submission to compare equivalency of the Magnitude 3150/3155 MRI Patient Monitoring System and the Integrated Patient Monitoring System 510(k) cleared devices to the modified 3160 MRI Patient Monitoring System met the performance requirements for accuracy and precision and indicates substantial equivalence to the predicate devices. Equivalent performance in meeting user requirements was also determined.
Summary of Performance Testing:
Validation and Verification Testing confirmed that the modified device operates as designed and intended. A summary of this testing is as follows:
This device was validated using a 3.0T MRI System as a worst-case environment. These devices were validated by verifying proper operation of the device while being subjected to 3.0T magnetic fields using simulators and test equipment under actual use conditions. Two scans, TRUE-FISP and PLANAR-ECHO, were used in both magnetic fields to simulate normal and worst-case MRI conditions.
| End Tidal CO2 Monitoring (Capnometer) | ||
|---|---|---|
| Parameter | Specification | Pass/Fail |
| Measurement Range | 0-76 mmHg | Pass |
| Accuracy | ±2mmHg + 5% of reading | Pass |
| Flow Rate | 50 mL/min | Pass |
| Respiration Rate | 0 to 100 BPM | Pass |
| Zero Drift Rate | 0.5 mmHg/hr; 1.5 mmHg/24hr | Pass |
| Alarm Limits | Lower: Off, 5 to 60 mmHgUpper: Off, 5 to 80 mmHg | Pass |
| Inspired CO2 | 25 mmHg | Pass |
{3}------------------------------------------------
INVIVO CORPORATION
1053-62
510(K) NOTIFICATION 3160 MRI PATIENT MONITORING SYSTEM
| Invasive Pressure Monitoring | ||
|---|---|---|
| Parameter | Specification | Pass/Fail |
| Channels | 1 or 2 simultaneous channels | Pass |
| Bandwidth (-3dB) | 0 to 12 Hz | Pass |
| Range | -10 to +248 mmHg | Pass |
| Sensitivity | 5 uV/V/mmHg | Pass |
| Gain Accuracy | $\pm$ 0.5 % | Pass |
| Auto Zero Feature | Zeroes with +/- 300 mmHg offset to 0+/- 5 mmHg within1 second | Pass |
| Waveform Display Scales | 0 to 45, 0 to 75, 0 to 150, 0 to 200,0 to 250 mmHg | Pass |
| High Pressure Alarm | 5 to 248 mmHg range; 1 mmHg resolution | Pass |
| Low Pressure Alarm | 5 to 248 mmHg range; 1 mmHg resolution | Pass |
| Temperature Monitoring | ||
|---|---|---|
| Parameter | Specification | Pass/Fail |
| Temperature Range | 25 to 44°C(77° to 111.2°F) | Pass |
| Accuracy | ± 0.5°C (± 0.5°F) | Pass |
| Resolution | ± 0.1°C (± 0.18°F) | Pass |
| Respiration Monitoring | ||
|---|---|---|
| Parameter | Specification | Pass/Fail |
| Range | 4 to 150 BPM | Pass |
| Resolution | 1 BPM | Pass |
| Accuracy | 2% to 60 BPM, 3.4% at 87 BPM, 5.6% at 142 BPM | Pass |
Conclusion:
The verification and validation activities for the 3160 MRI Patient Monitoring System confirm that all identified risks have been mitigated and that this device operates as designed and intended. The test results demonstrate the revised 3160 MRI Patient Monitoring System is substantially equivalent to the device cleared to market via 510(k) \ K050399 and the other predicate devices identified in this submittal.
Confidential
{4}------------------------------------------------
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 1 8 2006
Invivo Corporation c/o Mr. John Racette Quality Assurance and Regulatory Affairs Manager 12601 Research Parkway Orlando, FL 32826
Re: K053462
Trade Name: 3160 MRI Patient Monitor Regulation Number: 21 CFR 870.2300 Regulation Name: Physiological Patient Monitor Regulatory Class: Class II (two) Product Code: MWI Dated: December 6, 2005 Received: December 13, 2005
Dear Mr. Racette:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{5}------------------------------------------------
Page 2 – Mr. John Racette
Please be advised that FDA's issuance of a substantial equivalence determination does not mean 1 lease be advisou that 1 Dr o lation that your device complies with other requirements of the Act that I DA has made a acterimalations administered by other Federal agencies. You must of any I cueral statutes and regaranents, including, but not limited to: registration and listing (21 Comply with an the Not of Not of CFR Part 801); good manufacturing practice requirements as set CITY art 0077, idocinig (21 CFR Part 820); and if applicable, the electronic forth in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050. product radiation control provisions (2) = 1) = (2) = 1) = = 1 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = This letter will anow you is ought tinding of substantial equivalence of your device to a legally prematics notineation: The President for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you dosire specific acripliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small other general informational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Duna R. Vachner
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Indications for Use
510(k) Number (if known): Kos 346 Z
Device Name: 3160 MRI Patient Monitoring System
Indications for Use:
The 3160 MRI Patient Monitoring System is intended to monitor vital signs for patients undergoing MRI procedures and to provide signals for synchronization for the MRI scanner.
The 3160 MRI Patient Monitoring System is intended for use by health care professionals.
Prescription Use (Part 21 CFR 801 Subpart D)
... ... ... ... ... ... ... ... ... .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Duna R. Valuer
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Division Sign-Off) (Division Sign-Old)
Division of Cardiovascular Devices
510(K) Number_Les Les State
Page of of __
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).